<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03212157</url>
  </required_header>
  <id_info>
    <org_study_id>13/0450</org_study_id>
    <nct_id>NCT03212157</nct_id>
  </id_info>
  <brief_title>GlucoCEST MRI in Oncology</brief_title>
  <official_title>Establishment of GlucoCEST MRI as a Biomarker in Cancer Translational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cancer Research UK</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University College, London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The roles of imaging in cancer may be divided into that of diagnosis and tumour detection,
      staging and assessment of response to treatment. Standard radiological techniques include
      ultrasound, Computed Tomography (CT), Magnetic Resonance Imaging (MRI) and Positron Emission
      Tomography (PET). A combination of imaging techniques is often necessary to differentiate
      between cancerous and normal tissue. Traditional imaging techniques identify cancers by their
      gross appearance and structural/ cellular characteristics, whilst PET do so by tracking
      glucose metabolism. PET owes its specificity to the high rate of glucose metabolism seen in
      most cancers. However it is not used routinely due to a lack of availability and high costs.
      In addition, PET is often used in combination with CT, which imparts a significant diagnostic
      radiation dose. This can increase an individual's risk of cancer, especially with childhood
      or early adult exposure. In contrast, MRI is more readily available and does not involve
      radiation. However its ability to detect cancer by tracking glucose metabolism has not been
      widely explored. Our group has recently developed a novel MRI technique called Gluco-CEST
      that can image glucose delivery, uptake and metabolism in cancer, therefore potentially
      allowing a radiation-free, one-stop imaging service that can be adapted to current generation
      of MRI scanners. This study aims to optimise the GlucoCEST technique, after which it will be
      rigorously tested and compared to standard imaging parameters and clinical or pathological
      reference standards to evaluate its diagnostic and predictive power across a number of cancer
      populations.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The technique involves administration of glucose solution either orally or intravenously.
      This is metabolised and concentrated into the intracellular compartment rapidly, which can be
      detected by GlucoCEST MRI. The abnormally high glucose uptake demonstrated by certain tumours
      is therefore potential biomarkers. At present this is already being investigated in head and
      neck cancer patients using oral glucose in a separate study. In this proposal we aim to
      utilise intravenous administration of glucose, which has been shown in pre-clinical studies
      to improve GlucoCEST signal, and thus likely to increase the detectability of cancer.

      This study aims to develop and assess GlucoCEST and other exchange-sensitive MRI measurements
      (denoted 'exchange-sensitive MRI' hereafter) using intravenous glucose in tumours and
      metastases, and evaluate its use as an imaging biomarker of tumour and treatment response.
      This project will:

        1. Establish an optimised bolus and infusion protocol of intravenous glucose to maximise
           exchange-sensitive MRI signal.

        2. Assess the reproducibility of exchange-sensitive MRI and initial proof-of-concept study
           in cancer patients

        3. Apply exchange-sensitive MRI in selected cancer types to assess its diagnostic and
           prognostic power.

      The initial optimisation study involves investigating the optimal regime of intravenous
      glucose administration for obtaining the optimal exchange-sensitive MRI signal. The second
      stage will see exchange-sensitive MRI being applied to patients in different cancer groups to
      assess its ability for detecting cancer.

      For the optimisation study, 20 healthy volunteers will be recruited. For the application
      study 80 patients (20 Hodgkin's lymphoma, 20 head and neck tumour, and 40 glioma) will be
      investigated. Most of these patients will be due for an MRI as part of their standard care
      pathway; in these cases exchange-sensitive MRI will be added to the standard imaging
      sequence. For those who are not otherwise due for MRI, both standard and exchange-sensitive
      MRI will be acquired.

      It is expected that the data generated from this study will inform the design of larger
      trials and will provide the framework for an improved imaging pathway in certain cancer
      groups in the future.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 6, 2017</start_date>
  <completion_date type="Anticipated">June 1, 2018</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Developing new biochemical imaging tracer</measure>
    <time_frame>4 years</time_frame>
    <description>Optimised exchange-sensitive MRI techniques using intravenous glucose. Evaluation of the added value of quantitative GlucoCEST imaging, derived using OM CEST analysis software, to standard multi-modality anatomical imaging</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessing diagnostic value of glucoCEST</measure>
    <time_frame>4 years</time_frame>
    <description>Exchange-sensitive MRI in selected cancer types to assess its potential diagnostic value. Pre-treatment and post-treatment quantitative GlucoCEST MRI will be evaluated for prediction of residual/recurrent disease against clinical outcome measures of DFS, TTP and OS.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Head and Neck Squamous Cell Carcinoma</condition>
  <condition>Lymphoma</condition>
  <condition>Glioma</condition>
  <arm_group>
    <arm_group_label>GT1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Optimsation of glucose infusion protocol outside the Magnetic Resonance Imaging (MRI) scanner in healthy volunteers. To establish an optimised bolus and safety of infusion protocol of intravenous glucose to maximise exchange sensitive MRI signal.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GT2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Optimsation of glucose infusion protocol inside the Magnetic Resonance Imaging (MRI) scanner in patient volunteers. To assess the reproducibility of these techniques and initial proof-of-concept study in cancer patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GT3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Use of glucoCEST technique in staging of head and neck SCC, lymphoma and gliomas and correlating diagnostic potential with standard imaging such as FDG PET. To apply exchange-sensitive MRI in selected cancer types to assess its diagnostic potential. To study of non-glucose endogenous exchange sensitive MRI signals in (a) Prostate Cancer and (b) high grade Glioma patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Glucose infusion</intervention_name>
    <description>Infusion of 20% dextrose (drug) and using this as an imaging tracer in detecting and staging tumours.</description>
    <arm_group_label>GT1</arm_group_label>
    <arm_group_label>GT2</arm_group_label>
    <arm_group_label>GT3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Magnetic Resonance Imaging (MRI)</intervention_name>
    <description>MRI scanners (device) use strong magnetic fields, radio waves, and field gradients to generate images of the organs in the body. Specifically using the MRI scanner with the infusion of dextrose in detecting and staging tumours.</description>
    <arm_group_label>GT2</arm_group_label>
    <arm_group_label>GT3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>FDG PET</intervention_name>
    <description>FDG is a sugar (glucose) labelled with a small amount of radioactivity which goes to parts of the body that use glucose for energy. PET/CT images are acquired on a single scanner. An FDG PET scan can be used to assess the presence, location and severity of cancers.</description>
    <arm_group_label>GT3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy Volunteers:

               1. No previous history of cancer

               2. No known renal impairment or an eGFR within a standard reference value if there
                  is a history of renal disease.

               3. Aged 18 or over with capacity to consent.

          -  Patient groups:

               1. Confirmed diagnosis of selected cancer types (head and neck, lymphoma and glioma)

               2. No known renal impairment or an eGFR within a standard reference value if there
                  is a history of renal disease

               3. Aged 18 or over with capacity to consent.

        Exclusion Criteria:

          -  For both groups:

               1. Confirmed diagnosis of selected cancer types (head and neck, lymphoma and glioma)

               2. Pregnancy

               3. Contradiction to MRI magnetic field (pacemaker, metallic implant, severe
                  claustrophobia, etc)

               4. Allergy to MR contrast agent (Gadolinium)

               5. Adult with Impaired capacity

               6. Deranged renal function with eGFR
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sola Adeleke, MBBS</last_name>
    <email>Sola.Adeleke@uclh.nhs.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shonit Punwani, MBBS PHD</last_name>
    <email>Shonit.Punwani@uclh.nhs.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University College London Hospital</name>
      <address>
        <city>London</city>
        <zip>NW1 2PG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sola Adeleke, MBBS</last_name>
      <email>Sola.Adeleke@uclh.nhs.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Walker-Samuel S, Ramasawmy R, Torrealdea F, Rega M, Rajkumar V, Johnson SP, Richardson S, Gon√ßalves M, Parkes HG, Arstad E, Thomas DL, Pedley RB, Lythgoe MF, Golay X. In vivo imaging of glucose uptake and metabolism in tumors. Nat Med. 2013 Aug;19(8):1067-72. doi: 10.1038/nm.3252. Epub 2013 Jul 7.</citation>
    <PMID>23832090</PMID>
  </reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 27, 2017</study_first_submitted>
  <study_first_submitted_qc>July 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 11, 2017</study_first_posted>
  <last_update_submitted>July 6, 2017</last_update_submitted>
  <last_update_submitted_qc>July 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

